Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
ATATcH Alternating Treatment Plans for Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 150
- Registration Number
- NCT05358548
- Locations
- 🇺🇸
RWJBarnabas Health - Monmouth Medical Center, Long Branch, New Jersey, United States
🇺🇸RWJBarnabas Health - Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 422
- Registration Number
- NCT05357846
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
- Conditions
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT05342636
- Locations
- 🇧🇷
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300), São Paulo, Sao Paulo, Brazil
🇫🇷Hopital Claude Huriez - CHU de Lille ( Site 1100), Lille, Nord, France
🇫🇷Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan ( Site 1104), Brest, Finistere, France
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
- Conditions
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 53
- Registration Number
- NCT05325632
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT05322499
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05319639
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05319730
- Locations
- 🇨🇱
Clínica UC San Carlos de Apoquindo ( Site 4405), Santiago, Region M. De Santiago, Chile
🇮🇹IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 32, Meldola, Emilia-Romagna, Italy
🇨🇳Chang Gung Memorial Hospital at Kaohsiung ( Site 4003), Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan
A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Shanghai Institute Of Biological Products
- Target Recruit Count
- 512
- Registration Number
- NCT05318443
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2022-04-07
- Target Recruit Count
- 78
- Registration Number
- NCT05316376
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 400
- Registration Number
- NCT05307705
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸DFCI, Boston, Massachusetts, United States
🇺🇸Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.